focus -WSS

focus

author：knowledge 2025-08-22 17:22:53 - browse：54

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： FDA weighs limits of animal data in assessing artificial wombs

WSS

Solving academic medical centers' existential crisis

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Readers respond to H5N1 and livestock movements, and more

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Wearables generate powerful data but its not useful to doctors, yet

focus

focus

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

White House Covid adviser calls on docs to combat misinformation

United colonoscopy coverage change 'may cost lives,' doctors say

How the messy conversation about Dolly changed bioethics

At least 13 dead in Texas as scorching temps continue

Venture capitalist Bob Kocher on the state of digital health

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What happened to the House vote on health price transparency?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

'A game

focus

PBMs drew scrutiny in House hearing — and so did pharma

Venture capitalist Bob Kocher on the state of digital health

Addiction experts warn against a second 'war on drugs'

It's time to retire 'poor historian' from clinicians' vocabularies

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Free Covid tests will again be offered to all U.S. households

hotspot

hotspot

knowledge

hotspot